...4的病人Her-2基因过度表达，临床表现为恶性度较高，容易转移和复发并对治疗性药物抗拒，预后一般都不好。问题3：曲妥珠单抗(trastuzumab，赫赛汀)是个什么鬼?赫赛汀为一种重组DNA人源化IgG单克隆抗体。
基于7019个网页-相关网页
Trastuzumab Injection 注射用曲妥珠单抗 ; 曲妥珠单抗 ; 赫赛汀
Trastuzumab For Injection 注射用曲妥珠单抗
Trastuzumab For Inje 注射用曲妥珠单抗
Trastuzumab For 注射用曲妥珠单抗
trastuzumab f injection 注射用曲妥珠单抗
Trastuzumab Fo 注射用曲妥珠单抗
Trastuzumab For In 注射用曲妥珠单抗
Mean duration of trastuzumab treatment was 13 weeks(8-16 weeks).
曲妥珠单抗新辅助治疗的平均时间为13周(8周-16周)。
参考来源 - 紫杉醇联合卡铂每周方案在乳腺癌新辅助化疗中的临床和基础研究·2,447,543篇论文数据，部分数据来源于NoteExpress
In early use, trastuzumab is approved for use following standard (adjuvant) chemotherapy.
在早期使用中，曲妥珠单抗可作为以后的标准化化疗药物。
They also found that this synergy occurred with trastuzumab and either paclitaxel or vincristine.
他们发现这种协同作用也发生在脂质体和长春新碱或紫杉醇。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
应用推荐